|
(PQ 6) Exploiting Frequent Alterations in the PRC2 Complex to Distinguish Benign Neurofibromas from Malignant Peripheral Nerve Sheath Tumors
|
1R21CA208723-01
|
$212,824
|
$212,824
|
BETTEGOWDA, CHETAN
|
JOHNS HOPKINS UNIVERSITY
|
|
Axl receptor signaling in MPNST; potential node for therapy
|
4K08CA160443-05
|
$170,618
|
$85,309
|
TORRES, KEILA
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Cancer Center Support Grant
|
3P30CA082103-18S1
|
$121,856
|
$1,219
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18S2
|
$155,534
|
$1,555
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18S3
|
$60,000
|
$600
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18S4
|
$80,100
|
$801
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18S5
|
$200,000
|
$2,000
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18S6
|
$152,100
|
$1,521
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18S7
|
$200,000
|
$2,000
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18S8
|
$749,207
|
$7,492
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
4P30CA082103-18
|
$7,063,742
|
$70,637
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA091842-15S1
|
$124,686
|
$2,494
|
EBERLEIN, TIMOTHY
|
WASHINGTON UNIVERSITY
|
|
Cancer Center Support Grant
|
3P30CA091842-15S2
|
$149,999
|
$3,000
|
EBERLEIN, TIMOTHY
|
WASHINGTON UNIVERSITY
|
|
Cancer Center Support Grant
|
3P30CA091842-15S3
|
$497,258
|
$9,945
|
EBERLEIN, TIMOTHY
|
WASHINGTON UNIVERSITY
|
|
Cancer Center Support Grant
|
5P30CA091842-15
|
$4,305,712
|
$86,114
|
EBERLEIN, TIMOTHY
|
WASHINGTON UNIVERSITY
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
3P30CA142543-07S1
|
$200,000
|
$4,000
|
COBB, MELANIE
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
5P30CA142543-07
|
$2,479,396
|
$49,588
|
COBB, MELANIE
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Comprehensive Cancer Center Program at Fox Chase
|
2P30CA006927-51
|
$2,675,570
|
$267,557
|
FISHER, RICHARD
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
Comprehensive Cancer Center Program at Fox Chase
|
3P30CA006927-51S1
|
$250,000
|
$25,000
|
FISHER, RICHARD
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
Comprehensive Cancer Center Program at Fox Chase
|
3P30CA006927-51S2
|
$125,000
|
$12,500
|
FISHER, RICHARD
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
Comprehensive Cancer Center Program at Fox Chase
|
3P30CA006927-51S3
|
$133,875
|
$13,388
|
FISHER, RICHARD
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
Comprehensive Cancer Center Program at Fox Chase
|
3P30CA006927-51S4
|
$50,000
|
$5,000
|
FISHER, RICHARD
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
Comprehensive Cancer Center Program at Fox Chase
|
3P30CA006927-51S5
|
$59,999
|
$6,000
|
FISHER, RICHARD
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
Comprehensive Cancer Center Program at Fox Chase
|
3P30CA006927-51S6
|
$200,000
|
$20,000
|
FISHER, RICHARD
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
DEFINING RISK FACTORS FOR NF1-OPTIC GLIOMA
|
1R01CA214146-01A1
|
$348,844
|
$348,844
|
GUTMANN, DAVID
|
WASHINGTON UNIVERSITY
|
|
Developing Endpoints to Facilitate Clinical Trials in Rare Diseases
|
1R13CA203289-01
|
$3,993
|
$3,993
|
PLOTKIN, SCOTT
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Development of Natural Product Leads as Anticancer Therapeutics
|
ZIA BC 011470
|
$280,052
|
$56,010
|
Beutler, John
|
CCR (NCI)
|
|
Developmental and HyperActive Ras Tumor SPORE
|
5U54CA196519-02
|
$2,162,000
|
$1,816,080
|
CLAPP, DAVID
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
Elucidating the Regulation and Function of the NF1 tumor suppressor
|
2R01CA111754-11A1
|
$316,635
|
$316,635
|
CICHOWSKI, KAREN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Exploration of Activity of RAD001 in vivo in Vestibular Schwannomas and Meningiom
|
4R01CA164295-05
|
$1
|
$1
|
KARAJANNIS, MATTHIAS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
Families at high risk of cancer
|
ZIA CP004410-08285
|
$198,789
|
$13,915
|
Caporaso, Neil
|
DCEG (NCI)
|
|
Genomic dissection of tumor heterogeneity and progression
|
ZIA BC 011734
|
$141,223
|
$141,223
|
Shern, John
|
CCR (NCI)
|
|
Hodgkin's families
|
ZIA CP004410-08167
|
$30,637
|
$13,787
|
Goldin, Lynn
|
DCEG (NCI)
|
|
New Ways of Targeting K-Ras
|
1R35CA197709-01
|
$932,874
|
$466,437
|
MCCORMICK, FRANK
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Pediatric Oncology Branch Behavioral Science Core
|
ZID BC 011517
|
$835,175
|
$417,587
|
Glod, John
|
CCR (NCI)
|
|
Pediatric Oncology Branch Clinical Care and Education
|
ZIE BC 011516
|
$3,340,699
|
$668,140
|
Glod, John
|
CCR (NCI)
|
|
Phase II trial of mTORC1/mTORC2 inhibitor AZD2014 for sporadic meningioma
|
1R01CA201130-01A1
|
$400,389
|
$400,389
|
RAMESH, VIJAYA
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Role of Neurotrophins in the Development of the Mammalian Nervous System
|
ZIA BC 010390
|
$509,589
|
$101,918
|
Tessarollo, Lino
|
CCR (NCI)
|
|
Role of STE20 protein kinases in malignant mesothelioma
|
2R01CA148805-06
|
$423,938
|
$423,938
|
CHERNOFF, JONATHAN
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
SARC Sarcoma SPORE
|
3U54CA168512-05S1
|
$47,692
|
$4,292
|
BAKER, LAURENCE
|
SARC
|
|
SARC Sarcoma SPORE
|
4U54CA168512-05
|
$2,161,999
|
$194,580
|
BAKER, LAURENCE
|
SARC
|
|
SEVERABLE FUNDING FOR NCI-FREDERICK
|
261200800001E
|
$248,730,791
|
$13,348
|
UNKNOWN, UNKNOWN
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
Study of Anti-Survival signals in NF1
|
4R01CA153354-05
|
$322,663
|
$322,663
|
CHEN, CHANGYAN
|
NORTHEASTERN UNIVERSITY
|
|
Targeting the Kinome in Neurofibromatosis type 1
|
5R01CA142928-07
|
$423,938
|
$423,938
|
CHERNOFF, JONATHAN
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
The Roles of Tumor Microenvironment in Neurofibroma Development and Therapeutics
|
4R01CA166593-05
|
$329,925
|
$329,925
|
LE, LU
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Therapy for NF1-Related Tumors and other Genetic Tumor Predisposition Syndromes
|
ZIA BC 010801
|
$689,174
|
$689,174
|
Widemann, Brigitte
|
CCR (NCI)
|
Total relevant funding to Neurofibromatosis for this search: $8,057,361
|